Serina Therapeutics

Serina Therapeutics

Serina Therapeutics operates as a clinical-stage biotechnology company. It focuses on polymer-drug conjugate technology derived from polyoxazoline chemistry. The firm's platform is designed to modify small molecules, peptides, and oligonucleotides to extend their circulation time and improve tissue-specific delivery profiles. The lead clinical program centers on SER-252, a polymer-conjugated form of apomorphine being developed for advanced Parkinson's disease. The compound is designed to enable continuous dopaminergic stimulation via subcutaneous administration, seeking to reduce the dyskinesia and pulsatile motor fluctuations associated with current oral therapies. Preclinical work has also explored polyoxazoline conjugates for oncology and metabolic indications. The company has historically maintained a small physical footprint, operating out of Huntsville, Alabama. As of 2024, Serina announced a merger transaction with AgeX Therapeutics, a publicly listed longevity and regenerative medicine company. The deal was structured to create a combined entity focused on age-related degenerative diseases and was intended to provide access to public capital markets through AgeX's NYSE American listing. The ability to attract a reverse-merger partner suggests ongoing investor interest in the delivery platform, though precise capital deployment figures remain undisclosed. The firm's most unusual structural feature is its concentration of operations outside traditional biotech hubs, in Huntsville, Alabama. This location, while atypical, connects Serina to a specialized polymer chemistry talent pool and a lower-cost research infrastructure base relative to Boston or San Francisco peers. The reverse-merger with AgeX also represents a structural pivot aimed at accelerating pathway to clinical milestones through public-market financing, positioning the combined company at the intersection of neurology and age-related degeneration research.